Zymeworks (ZYME) Other Non-Current Assets (2021 - 2026)
Zymeworks (ZYME) posted Other Non-Current Assets of $6.7 million for Q1 2026, little changed sequentially from $6.7 million in Q4 2025, and down 26.87% YoY from $9.1 million in Q1 2025.
Analysis
Zymeworks (ZYME) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Zymeworks has reported Other Non-Current Assets for 6 years, with the latest figure at $6.7 million in Q1 2026.
- Quarterly Other Non-Current Assets fell 26.87% year-over-year to $6.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.7 million (down 26.87% YoY) and the FY2025 annual result came in at $6.7 million, down 25.17% from the prior year.
- Other Non-Current Assets was little changed at $6.7 million in Q1 2026 per ZYME's latest filing, from $6.7 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $16.9 million in Q1 2023 and troughed at $6.7 million in Q1 2026.
- A 5-year average of $9.5 million and a median of $7.9 million in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets increased 25.93% in 2022, then tumbled 54.54% in 2024.
- Over 5 years, Other Non-Current Assets stood at $15.7 million in 2022, then slumped by 51.9% to $7.6 million in 2023, then advanced by 17.88% to $8.9 million in 2024, then decreased by 25.17% to $6.7 million in 2025, then fell by 0.33% to $6.7 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $6.7 million, $6.7 million, and $7.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Zymeworks | 2.13 Bn | 1.86 Bn | - | 2.28 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.28 Mn |
| Mar 31, 2026 | 6.65 Mn |
| Dec 31, 2025 | 6.67 Mn |
| Sep 30, 2025 | 7.39 Mn |
| Jun 30, 2025 | 8.86 Mn |
| Mar 31, 2025 | 9.10 Mn |
| Dec 31, 2024 | 8.92 Mn |
| Sep 30, 2024 | 7.23 Mn |
| Jun 30, 2024 | 7.18 Mn |
| Mar 31, 2024 | 7.68 Mn |
| Dec 31, 2023 | 7.57 Mn |
| Sep 30, 2023 | 8.29 Mn |
| Jun 30, 2023 | 7.91 Mn |
| Mar 31, 2023 | 16.89 Mn |
| Dec 31, 2022 | 15.73 Mn |
| Sep 30, 2022 | 16.45 Mn |
| Dec 31, 2021 | 12.49 Mn |